A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States

Hepatitis B vaccination is the most effective measure to prevent hepatitis B virus (HBV) infection and its consequences, including cirrhosis of the liver, liver cancer, liver failure, and death. In adults, ongoing HBV transmission occurs primarily among unvaccinated persons with behavioral risks for HBV transmission (e.g., heterosexuals with multiple sex partners, injection-drug users [IDUs], and men who have sex with men [MSM]) and among household contacts and sex partners of persons with chronic HBV infection. This report, the second of a two-part statement from the Advisory Committee on Immunization Practices (ACIP), provides updated recommendations to increase hepatitis B vaccination of adults at risk for HBV infection. The first part of the ACIP statement, which provided recommendations for immunization of infants, children, and adolescents, was published previously (CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of infants, children, and adolescents. MMWR 2005;54[No. RR-16]:1-33). In settings in which a high proportion of adults have risks for HBV infection (e.g., sexually transmitted disease/human immunodeficiency virus testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting services to IDUs, health-care settings targeting services to MSM, and correctional facilities), ACIP recommends universal hepatitis B vaccination for all unvaccinated adults. In other primary care and specialty medical settings in which adults at risk for HBV infection receive care, health-care providers should inform all patients about the health benefits of vaccination, including risks for HBV infection and persons for whom vaccination is recommended, and vaccinate adults who report risks for HBV infection and any adults requesting protection from HBV infection. To promote vaccination in all settings, health-care providers should implement standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine clinical services, not require acknowledgment of an HBV infection risk factor for adults to receive vaccine, and use available reimbursement mechanisms to remove financial barriers to hepatitis B vaccination.

[1]  Robert T. Chen,et al.  Hepatitis B vaccine and risk of multiple sclerosis , 2002, Expert review of vaccines.

[2]  Wen-Hung Kuo,et al.  ASIAN POPULATION , 2007 .

[3]  M. Weinstein,et al.  Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. , 2006, American journal of preventive medicine.

[4]  J. Gerberding,et al.  Morbidity and Mortality Weekly Report Prevention of Hepatitis a through Active or Passive Immunization Recommendations of the Advisory Committee on Immunization Practices (acip) Centers for Disease Control and Prevention Coordinating Center for Health Information and Service Recommendations and Repo , 2022 .

[5]  A. Lok,et al.  Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005 , 2006, Hepatology.

[6]  W. Jilg,et al.  Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. , 2006, Vaccine.

[7]  B. Bell,et al.  Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users , 2005, Journal of Urban Health.

[8]  R. D. Bruce,et al.  Adherence to hepatitis B virus vaccination at syringe exchange sites , 2005, Journal of Urban Health.

[9]  M. Alter,et al.  Epidemiology of viral hepatitis and HIV co-infection. , 2006, Journal of hepatology.

[10]  H. Margolis,et al.  A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[11]  Fangjun Zhou,et al.  A mathematical model to estimate global hepatitis B disease burden and vaccination impact. , 2005, International journal of epidemiology.

[12]  A. Zanetti,et al.  Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study , 2005, The Lancet.

[13]  C. Dentinger.  Anti-HBs Persistence and Response to a Hepatitis B (HB) Vaccine Boost among Yup’ik Eskimos 23 Years after HB Vaccination , 2005 .

[14]  I. Williams.  Missed Opportunities for Hepatitis B Vaccination in Correctional Settings, Sexually Transmitted Disease (STD) Clinics, and Drug Treatment Programs , 2005 .

[15]  A. Panlilio,et al.  Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[16]  H. Margolis,et al.  Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. , 2005, American journal of preventive medicine.

[17]  C. Weinbaum,et al.  Integrating Hepatitis B Prevention Into Sexually Transmitted Disease Services: U.S. Sexually Transmitted Disease Program and Clinic Trends—1997 and 2001 , 2005, Sexually transmitted diseases.

[18]  A. Barone,et al.  Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. , 2005, Vaccine.

[19]  M. Hernán,et al.  Recombinant hepatitis B vaccine and the risk of multiple sclerosis : A prospective study. Authors' reply , 2005 .

[20]  Robert T. Chen,et al.  Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. , 2005, Neurology.

[21]  J. Dienstag.  Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infection , 1981, Springer Seminars in Immunopathology.

[22]  S. Cole,et al.  Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  S. Blank,et al.  Predictors of Acceptance of Hepatitis B Vaccination in an Urban Sexually Transmitted Diseases Clinic , 2004, Sexually transmitted diseases.

[24]  S. Stokley,et al.  Factors associated with receiving hepatitis B vaccination among high-risk adults in the United States: an analysis of the National Health Interview Survey, 2000. , 2004, Family medicine.

[25]  N. Horton,et al.  Assessing missed opportunities for HIV testing in medical settings , 2004, Journal of general internal medicine.

[26]  B. McMahon,et al.  Chronic hepatitis B: Update of recommendations , 2004, Hepatology.

[27]  R. Davis,et al.  Risk of anaphylaxis after vaccination of children and adolescents. , 2003, Pediatrics.

[28]  T. Strine,et al.  Hepatitis A and B Vaccination in a Sexually Transmitted Disease Clinic for Men Who Have Sex With Men , 2003, Sexually transmitted diseases.

[29]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[30]  G. Schreiber,et al.  Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection , 2003, Transfusion.

[31]  Robert T. Chen,et al.  Vaccinations and risk of central nervous system demyelinating diseases in adults. , 2003, Archives of neurology.

[32]  G. Drusano,et al.  Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. , 2003, Vaccine.

[33]  D. Vlahov,et al.  Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. , 2003, American journal of epidemiology.

[34]  J. Rich,et al.  A review of the case for hepatitis B vaccination of high-risk adults. , 2003, The American journal of medicine.

[35]  H. Margolis,et al.  Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination , 2003, The Pediatric infectious disease journal.

[36]  H. Margolis,et al.  Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[37]  J. Banatvala,et al.  Hepatitis B vaccine – do we need boosters? , 2003, Journal of viral hepatitis.

[38]  H. Hsu,et al.  Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. , 2003, The Journal of infectious diseases.

[39]  D. Shouval.  Hepatitis B vaccines. , 2003, Journal of hepatology.

[40]  Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002. , 2003, MMWR. Morbidity and mortality weekly report.

[41]  S. Rosenbaum,et al.  The Epidemiology of U.S. Immunization Law: A National Study for the National Immunizations Program, Centers for Disease Control and Prevention: Medicaid Coverage of Immunizations for Non-Institutionalized Adults , 2003 .

[42]  M. Meltzer,et al.  Cost-effectiveness of hepatitis B vaccination of prison inmates. , 2002, Vaccine.

[43]  J. S. St. Lawrence,et al.  STD screening, testing, case reporting, and clinical and partner notification practices: a national survey of US physicians. , 2002, American journal of public health.

[44]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[45]  B. Woodruff,et al.  Prevalence of hepatitis virus infections in an institution for persons with developmental disabilities. , 2002, American journal of mental retardation : AJMR.

[46]  H. Margolis,et al.  Occupational Exposures and Risk of Hepatitis B Virus Infection Among Public Safety Workers , 2002, Journal of occupational and environmental medicine.

[47]  Robert T. Chen,et al.  Childhood vaccinations and risk of asthma , 2002, The Pediatric infectious disease journal.

[48]  H. Margolis,et al.  Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. , 2002, The Journal of infectious diseases.

[49]  M. Gwinn,et al.  Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. , 2002, American journal of public health.

[50]  M. Samuel,et al.  Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA , 2001, Epidemiology and Infection.

[51]  J P Mullooly,et al.  Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. , 2001, Pediatrics.

[52]  D. Konstantinou,et al.  Two episodes of leukoencephalitis associated with recombinant hepatitis B vaccination in a single patient. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  B. McMahon,et al.  Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus , 2001, Annals of Internal Medicine.

[54]  H. Margolis,et al.  Childhood hepatitis B virus infections in the United States before hepatitis B immunization. , 2001, Pediatrics.

[55]  Ding‐Shinn Chen,et al.  Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus , 2001, Hepatology.

[56]  R. Janssen,et al.  Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. , 2001, American journal of public health.

[57]  L. Barker,et al.  National, state and urban-area vaccination-coverage levels among children aged 19-35 months, United States, 1999. , 2001, American journal of preventive medicine.

[58]  E. Mast,et al.  Preventing transmission of hepatitis B virus from people with chronic infection. , 2001, American journal of preventive medicine.

[59]  J. Rich,et al.  Hepatitis B Vaccination Practices in State and Federal Prisons , 2001, Public health reports.

[60]  Jerome I. Tokars,et al.  Recommendations for preventing transmission of infections among chronic hemodialysis patients , 2001 .

[61]  P. Kerndt,et al.  Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994-1996. , 2001, Addiction.

[62]  H. Margolis,et al.  Screening for Chronic Hepatitis B and C Virus Infections in an Urban Sexually Transmitted Disease Clinic: Rationale for Integrating Services , 2001, Sexually transmitted diseases.

[63]  S Suissa,et al.  Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. , 2001, The New England journal of medicine.

[64]  A M Walker,et al.  Hepatitis B vaccination and the risk of multiple sclerosis. , 2001, The New England journal of medicine.

[65]  J. Gerberding,et al.  Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. , 2001, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[66]  H. Margolis,et al.  Serological pattern “anti‐HBc alone”: Report on a workshop , 2000, Journal of medical virology.

[67]  Bell Bp.  Hepatitis A and hepatitis B vaccination of patients with chronic liver disease. , 2000 .

[68]  W. Cook,et al.  Prolonged hepatitis B surface antigenemia after vaccination. , 2000, Pediatrics.

[69]  A. Moscicki,et al.  Seroprevalence and Risk Factors of Hepatitis B, Hepatitis C, and Human Cytomegalovirus Among HIV‐Infected and High‐Risk Uninfected Adolescents: Findings of the REACH Study , 2000 .

[70]  M. Hussey,et al.  A successful approach to immunizing men who have sex with men against hepatitis B. , 2000, Public health nursing.

[71]  L. Rodewald,et al.  Use of standing orders programs to increase adult vaccination rates. , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[72]  S. Oka,et al.  Influence of Prior HIV-1 Infection on the Development of Chronic Hepatitis B Infection , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[73]  H. Margolis,et al.  Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. , 2000, The Journal of infectious diseases.

[74]  J. Lang,et al.  Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. , 2000, Vaccine.

[75]  B. Bell.  Hepatitis A and hepatitis B vaccination of patients with chronic liver disease. , 2000, Acta gastro-enterologica Belgica.

[76]  L. Levin,et al.  Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: findings of the REACH Study. Adolescent Medicine HIV/AIDS Research Network. , 2000, Sexually transmitted diseases.

[77]  J. Fortenberry,et al.  Practice patterns for the elicitation of sexual history, education, and counseling among providers of STD services: results from the gonorrhea community action project (GCAP). , 1999, Sexually transmitted diseases.

[78]  E. Vignon,et al.  Rheumatic disorders developed after hepatitis B vaccination. , 1999, Rheumatology.

[79]  M. Rivard,et al.  Do physicians assess lifestyle health risks during general medical examinations? A survey of general practitioners and obstetrician-gynecologists in Quebec. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[80]  L. Hwang,et al.  Hepatitis B vaccination in high-risk infants: 10-year follow-up. , 1999, The Journal of infectious diseases.

[81]  H. Margolis,et al.  Hepatitis B Vaccine Administered to Children and Adolescents at Yearly Intervals , 1999, Pediatrics.

[82]  A. Tärnvik,et al.  Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. , 1999, Vaccine.

[83]  H. Whittle,et al.  What level of hepatitis B antibody is protective? , 1999, The Journal of infectious diseases.

[84]  N. Weiss,et al.  Syringe exchange and risk of infection with hepatitis B and C viruses. , 1999, American journal of epidemiology.

[85]  H. Margolis,et al.  Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board. , 1999, The Pediatric infectious disease journal.

[86]  J. Pope,et al.  The development of rheumatoid arthritis after recombinant hepatitis B vaccination. , 1998, The Journal of rheumatology.

[87]  H. Margolis,et al.  Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. , 1998, American journal of preventive medicine.

[88]  B. McMahon,et al.  Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  M. Alter,et al.  Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. , 1997, Archives of internal medicine.

[90]  M. Salive,et al.  Hair loss after routine immunizations. , 1997, JAMA.

[91]  H. Werman,et al.  Seroprevalence of hepatitis B and hepatitis C among rural emergency medical care personnel. , 1997, The American journal of emergency medicine.

[92]  P. Goldwater.  Randomized, comparative trial of 20 μg vs 40 μg Engerix B vaccine in hepatitis B vaccine non-responders , 1997 .

[93]  J. Kruppenbacher,et al.  Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance. , 1997, Vaccine.

[94]  G. Poland,et al.  A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. , 1997, The Journal of infectious diseases.

[95]  S. Lemon,et al.  Vaccines to prevent viral hepatitis. , 1997, The New England journal of medicine.

[96]  P. Goldwater.  Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. , 1997, Vaccine.

[97]  H. Ohara,et al.  Prophylaxis of acute viral hepatitis by immune serum globulin, hepatitis B vaccine, and health education: a sixteen year study of Japan overseas cooperation volunteers. , 1997, The American journal of tropical medicine and hygiene.

[98]  H. Pennington.  Childhood immunisation and diabetes mellitus. , 1996 .

[99]  R. Brookmeyer,et al.  Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users. , 1996, The Journal of infectious diseases.

[100]  M. McDiarmid,et al.  Prevalence of antibodies to hepatitis B and C among fire department personnel prior to implementation of a hepatitis B vaccination program. , 1996, Journal of occupational and environmental medicine.

[101]  S. Kleinman,et al.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. , 1996, The New England journal of medicine.

[102]  J. Classen.  Childhood immunisation and diabetes mellitus. , 1996, The New Zealand medical journal.

[103]  R. Harpaz,et al.  Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1996, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[104]  M. Tormey,et al.  Outbreaks of hepatitis B virus infection among hemodialysis patients-- California, Nebraska, and Texas, 1994. , 1996, MMWR. Morbidity and mortality weekly report.

[105]  T. Farley,et al.  Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. , 1995, Pediatrics.

[106]  M. Rivard,et al.  STD risk assessment and risk‐reduction counseling by recently trained family physicians , 1995, Academic medicine : journal of the Association of American Medical Colleges.

[107]  B. Grossman,et al.  Hepatitis B surface antigenemia in blood donors following vaccination , 1995, Transfusion.

[108]  K. Hyams.  Risks of chronicity following acute hepatitis B virus infection: a review. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[109]  B. Cooper,et al.  Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. , 1995, Infection control and hospital epidemiology.

[110]  V. Peters,et al.  RESPONSES TO HEPATITIS B VACCINE BOOSTERS IN HUMAN , 1995, The Pediatric infectious disease journal.

[111]  A. Zuckerman,et al.  Protective efficacy of hepatitis B vaccines in neonates , 1994, Journal of medical virology.

[112]  R. Johnston,et al.  Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. , 1994, JAMA.

[113]  M. Alter,et al.  Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. , 1994, The Journal of infectious diseases.

[114]  J. Horváth,et al.  Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[115]  D. Nalin.  Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality , 1994, The Yale Journal of Biology and Medicine.

[116]  L. Neumann,et al.  Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. , 1994, Journal of hepatology.

[117]  M. Osterholm,et al.  Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. , 1993, JAMA.

[118]  W. Hlady,et al.  Patient-to-patient transmission of hepatitis B in a dermatology practice. , 1993, American journal of public health.

[119]  H. Margolis,et al.  Blood exposure and the risk of hepatitis B virus infection in firefighters. , 1993, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[120]  A J Hall,et al.  The influence of age on the development of the hepatitis B carrier state , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[121]  D. Greenberg.  Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. , 1993, The Pediatric infectious disease journal.

[122]  F. Trevisani,et al.  Transverse myelitis following hepatitis B vaccination. , 1993, Journal of hepatology.

[123]  S. Kaneko,et al.  Clearance of HBsAg in seven patients with chronic hepatitis B , 1992, Hepatology.

[124]  B. McMahon,et al.  Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. , 1992, Gastroenterology.

[125]  P. Toy,et al.  Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. , 1992, Pediatrics.

[126]  A. House.  Alleged link between hepatitis B vaccine and chronic fatigue syndrome. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[127]  H. Margolis,et al.  Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device. , 1992, The New England journal of medicine.

[128]  E. Yeoh,et al.  Significance of isolated anti‐HBc seropositivity by ELISA: Implications and the role of radioimmunoassay , 1992, Journal of medical virology.

[129]  J. P. Davis,et al.  Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. , 1992, Pediatrics.

[130]  M. Bruguera,et al.  Impaired Response to Recombinant Hepatitis B Vaccine in HIV‐Infected Persons , 1992, Journal of clinical gastroenterology.

[131]  P. Tudela,et al.  Systemic lupus erythematosus and vaccination against hepatitis B. , 1992, Nephron.

[132]  S. O'Sullivan.  Alleged link between hepatitis B vaccine and chronic fatigue syndrome. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[133]  J. Keyser,et al.  Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine , 1991, The Lancet.

[134]  S. Kashiwagi,et al.  Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. , 1991, JAMA.

[135]  G. Koren,et al.  Hepatitis B Vaccine in Pregnancy: Maternal and Fetal Safety , 1991, American journal of perinatology.

[136]  J. Hoofnagle,et al.  Serologic Diagnosis of Acute and Chronic Viral Hepatitis , 1991, Seminars in liver disease.

[137]  C. Chu,et al.  Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study , 1991, Hepatology.

[138]  S. Hadler,et al.  Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. , 1991, The Journal of infectious diseases.

[139]  J. Frame,et al.  High incidence of viral hepatitis among American missionaries in Africa. , 1990, The American journal of tropical medicine and hygiene.

[140]  H. Margolis,et al.  The emergence of hepatitis B as a sexually transmitted disease. , 1990, The Medical clinics of North America.

[141]  M. Alter,et al.  An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. , 1990, Archives of internal medicine.

[142]  A. Zuckerman,et al.  Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: An indicator of poor prognosis , 1990, Journal of medical virology.

[143]  H. Margolis,et al.  The Changing Epidemiology of Hepatitis B in the United States: Need for Alternative Vaccination Strategies , 1990 .

[144]  J. Stéphenne.  Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. , 1990, Vaccine.

[145]  R. Steffen.  Risks of hepatitis B for travellers. , 1990, Vaccine.

[146]  R. Sikes,et al.  Hepatitis B virus infection among children born in the United States to Southeast Asian refugees , 1990, The New England journal of medicine.

[147]  M. E. Levy,et al.  Hepatitis B virus transmission between children in day care , 1989, The Pediatric infectious disease journal.

[148]  F. Deinhardt,et al.  Vaccination against hepatitis B: comparison of three different vaccination schedules. , 1989, The Journal of infectious diseases.

[149]  S. Hadler,et al.  Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. , 1989, Vaccine.

[150]  A. Katz,et al.  Genetic prediction of nonresponse to hepatitis B vaccine. , 1989, The New England journal of medicine.

[151]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[152]  F. André.  Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. , 1989, The American journal of medicine.

[153]  K. Masuko,et al.  Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: Comparison with immune globulin without vaccine in historical controls , 1989, Hepatology.

[154]  S. Hadler,et al.  Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. , 1989, Vaccine.

[155]  Brunetto.  Identification of HBV variants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis , 1989 .

[156]  Morbidity and Mortality Weekly Report,et al.  Prevention of Perinatal Transmission of Hepatitis B Virus: Prenatal Screening of all Pregnant Women for Hepatitis B Surface Antigen , 1989 .

[157]  M. Tong,et al.  Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. , 1988, JAMA.

[158]  H. Handsfield,et al.  Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. , 1988, Annals of internal medicine.

[159]  G. Kent,et al.  A large outbreak of acupuncture-associated hepatitis B. , 1988, American journal of epidemiology.

[160]  S. Hadler,et al.  Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. , 1988, American journal of epidemiology.

[161]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.

[162]  J. Bossell.  Safety of Therapeutic Immune Globulin Preparations with Respect to Transmission of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus Infection , 1986, MMWR. Morbidity and mortality weekly report.

[163]  C. Crumpacker,et al.  Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. , 1986, Annals of internal medicine.

[164]  S. Hadler,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. , 1986, The New England journal of medicine.

[165]  E. Scolnick,et al.  Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. , 1986, The Journal of infection.

[166]  E. Scolnick,et al.  Production and immunological analysis of recombinant hepatitis B vaccine. , 1986, The Journal of infection.

[167]  G. Papaevangelou,et al.  Immunogenicity of a reduced dose of recombinant hepatitis B vaccine. , 1986, Vaccine.

[168]  M. Alter,et al.  Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. , 1986, The Journal of infectious diseases.

[169]  O. H. Lowry,et al.  Different operating conditions affect risk of hepatitis B virus infection at two residential institutions for the mentally disabled. , 1986, American journal of epidemiology.

[170]  J. Epstein,et al.  Inactivation and partition of human T‐cell lymphotrophic virus, type III, during ethanol fractionation of plasma , 1986, Transfusion.

[171]  G. Samsa,et al.  Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. , 1985, JAMA.

[172]  T R Bender,et al.  Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.

[173]  B. McMahon,et al.  The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. , 1985, The Journal of infectious diseases.

[174]  S. Hadler,et al.  Occupational Risk of Hepatitis B Infection in Hospital Workers , 1985, Infection Control.

[175]  W. Szmuness,et al.  Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. , 1984, The New England journal of medicine.

[176]  G. Storch,et al.  Survey of hepatitis B viral markers at a public day school and a residential institution sharing mentally handicapped students. , 1984, The Journal of infectious diseases.

[177]  R. Perrillo,et al.  Immune globulin and hepatitis B immune globulin. Prophylactic measures for intimate contacts exposed to acute type B hepatitis. , 1984, Archives of internal medicine.

[178]  L. Hwang,et al.  PREVENTION OF PERINATALLY TRANSMITTED HEPATITIS B VIRUS INFECTIONS WITH HEPATITIS B IMMUNE GLOBULIN AND HEPATITIS B VACCINE , 1983, The Lancet.

[179]  M. Alter,et al.  Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. , 1983, Annals of internal medicine.

[180]  J. Quinn.  Inactivated hepatitis B virus vaccine , 1983 .

[181]  M. Hilleman,et al.  Quality and safety of human hepatitis B vaccine. , 1983, Developments in biological standardization.

[182]  E. Schiff,et al.  An institutional outbreak of hepatitis B related to a human biting carrier. , 1982, The Journal of infectious diseases.

[183]  S. Hadler,et al.  The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. , 1982, Annals of internal medicine.

[184]  R. Sampliner,et al.  Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. , 1982, American journal of epidemiology.

[185]  D. M. Ryan,et al.  Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? , 1982, American journal of epidemiology.

[186]  M. Favero,et al.  SURVIVAL OF HEPATITIS B VIRUS AFTER DRYING AND STORAGE FOR ONE WEEK , 1981, The Lancet.

[187]  W. Bancroft,et al.  Experimental transmission of hepatitis B virus by semen and saliva. , 1980, The Journal of infectious diseases.

[188]  J. M. Morrison,et al.  Hepatitis B Vaccine , 1980, The Lancet.

[189]  N. Noah,et al.  AN OUTBREAK OF HEPATITIS B FROM TATTOOING , 1979, The Lancet.

[190]  I. Mushahwar,et al.  Viral hepatitis, type B. Studies on natural history and prevention re-examined. , 1979, The New England journal of medicine.

[191]  J. Senior,et al.  Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. , 1978, The Journal of infectious diseases.

[192]  R. Purcell,et al.  Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. , 1978, Annals of internal medicine.

[193]  E. Nordenfelt,et al.  HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B. , 1978, Scandinavian journal of infectious diseases.

[194]  M. Imai,et al.  Hepatitis B e antigen and infectivity of hepatitis B virus. , 1977, The Journal of infectious diseases.

[195]  R. Purcell,et al.  Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen , 1977, Infection and immunity.

[196]  R. Koff,et al.  Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. , 1977, Gastroenterology.

[197]  R. Chaudhary,et al.  Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. , 1977, American journal of epidemiology.

[198]  W. Bancroft,et al.  Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. , 1977, The Journal of infectious diseases.

[199]  R. Purcell,et al.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. , 1976, The New England journal of medicine.

[200]  R. Purcell,et al.  Radioimmunoassay for antibody to hepatitis B surface antigen shows transmission of hepatitis B virus among household contacts. , 1976, The Journal of infectious diseases.

[201]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[202]  J. Mosley,et al.  Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. , 1975, The New England journal of medicine.

[203]  B. Leventhal,et al.  The risk of hepatitis transmission to family contacts of leukemia patients. , 1975, The Journal of pediatrics.

[204]  R. Purcell,et al.  Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. , 1975, The American journal of the medical sciences.

[205]  B. Forghani,et al.  Hepatitis B transmitted by a human bite. , 1974, JAMA.

[206]  S. Sherlock,et al.  Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus. , 1974, Lancet.

[207]  W. Bancroft,et al.  Hepatitis B antigen and antibody. Occurrence in families of asymptomatic HB AG carriers. , 1974, JAMA.

[208]  M. Favero,et al.  Detection methods for study of the stability of hepatitis B antigen on surfaces. , 1974, The Journal of infectious diseases.